In the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to try out rheumatoid arthritis med Kevzara in desperately ill patients. But after early warning signs ...

Sanofi and Regeneron just added another building block to a nascent immunology franchise expected to bring in $5 billion or more by 2022. But to get there, their new Kevzara will have to go up ...

and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients ...

A day earlier, Regeneron (ticker: REGN) said it had started trials with its existing arthritis drug, Kevzara, which might prove useful in treating lung inflammation in Covid-19 patients ...

Yancopoulos, M.D., Ph.D., Regeneron Co-Founder, President and Chief Scientific Officer. "Emerging evidence with Kevzara and other repurposed drugs in the COVID-19 crisis highlight the challenges ...

Sanofi SNY and its collaboration partner, Regeneron Pharmaceuticals REGN intend to restructure their antibody collaboration into a royalty-based agreement for Kevzara (sarilumab) and Praluent ...

Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara ® (sarilumab ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Sarilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. KEVZARA ® (sarilumab) is an injectable prescription medicine called an interleukin-6 (IL-6 ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...